Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2014-05-16 Regulatory Filings
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings
2014-05-16 English
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a correspondence related to a capital raising filing, specifically a registration statement for securities offering. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an update on a financing activity, specifically requesting the SEC to declare the registration statement effective. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication, so it is not RPA. Confidence is high due to clear context and content.
2014-05-13 English
Regulatory Filings 2014
Regulatory Filings
2014-05-12 English
10-Q
Interim / Quarterly Report Q1 2014
2014-05-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2014, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2014. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 2971 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release of financial results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such SEC Form 8-K filings that announce but do not contain full financial reports.
2014-05-06 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-3 and references the filing of a definitive proxy statement related to the company's Annual Report on Form 10-K. The letter discusses procedural matters such as confidential treatment requests and acceleration of the registration statement's effectiveness. It does not contain financial data, audit results, or detailed report content but is a regulatory communication responding to SEC comments. The document length is short (2279 characters) and is clearly a regulatory correspondence rather than a full report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such communications.
2014-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.